

# Clara Hwang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2873050/publications.pdf>

Version: 2024-02-01

66  
papers

2,534  
citations

331259

21  
h-index

205818

48  
g-index

67  
all docs

67  
docs citations

67  
times ranked

3290  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world effectiveness of the pegfilgrastim on-body injector in preventing severe neutropenia. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 17-23.	0.5	4
2	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	2.0	15
3	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	2.8	9
4	Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac037.	0.4	8
5	Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. <i>The Lancet Healthy Longevity</i> , 2022, 3, e143-e152.	2.0	16
6	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	2.8	43
7	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. <i>Blood Cancer Discovery</i> , 2022, 3, 181-193.	2.6	12
8	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 953-963.	0.4	6
9	SPOP mutation as a predictive marker for treatment of metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 160-160.	0.8	2
10	Fractionated docetaxel and radium-223 (Ra223) in metastatic castration-resistant prostate cancer (CRPC): A phase I trial. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS175-TPS175.	0.8	0
11	Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 12035-12035.	0.8	1
12	Concomitant infections in patients with cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) study. <i>Journal of Clinical Oncology</i> , 2021, 39, 6561-6561.	0.8	0
13	Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study. <i>Journal of Clinical Oncology</i> , 2021, 39, 5042-5042.	0.8	4
14	Rapid real-world data analysis of patients with cancer, with and without COVID-19, across distinct health systems. <i>Cancer Reports</i> , 2021, 4, e1388.	0.6	5
15	Thrombotic complications with SARS-CoV-2 infection in patients with cancer on high-risk therapies: Data from the COVID-19 and Cancer Consortium (CCC19). <i>Journal of Clinical Oncology</i> , 2021, 39, e18788-e18788.	0.8	2
16	Effect of Bacillus Calmette-Guerin (BCG) exposure on severity of COVID-19 infection: A COVID-19 and Cancer Consortium (CCC19) study. <i>Journal of Clinical Oncology</i> , 2021, 39, 4529-4529.	0.8	0
17	Lower respiratory tract disease (LRTD) in patients with cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) study. <i>Journal of Clinical Oncology</i> , 2021, 39, 6563-6563.	0.8	0
18	Racial and ethnic disparities among patients with breast cancer and COVID-19. <i>Journal of Clinical Oncology</i> , 2021, 39, 6500-6500.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.. Journal of Clinical Oncology, 2021, 39, 11523-11523.	0.8	1
20	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 931-945.	5.1	337
21	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncology, 2021, 7, 1167.	3.4	149
22	The CoVIDâ€TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVIDâ€19. Journal of Thrombosis and Haemostasis, 2021, 19, 2522-2532.	1.9	23
23	The Potential and Limitations of Precision Oncology: Lessons Learned from Whole-Exome Sequencing in an Exceptional Response to Everolimus in Advanced Renal Cell Carcinoma. Case Reports in Oncology, 2021, 14, 1194-1200.	0.3	1
24	Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Network Open, 2021, 4, e2034633.	2.8	29
25	Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castrationâ€resistant prostate cancer. Prostate, 2021, 82, 182.	1.2	4
26	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA Network Open, 2021, 4, e2134330.	2.8	32
27	Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. Radiotherapy and Oncology, 2020, 151, 141-148.	0.3	62
28	Towards Evidence Based Practice: The American Radium Society (ARS) and American College of Radiology (ACR) Appropriate Use Guidelines on Radiation Therapy for Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, E34-E35.	0.4	0
29	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	7.7	26
30	Abstract 4100: Androgen receptor signaling dysregulates the mitotic checkpoint to mediate docetaxel resistance in castration-resistant prostate cancer. , 2020, , .		0
31	Class III Î²-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer. PLoS ONE, 2019, 14, e0222510.	1.1	13
32	Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. Neoplasia, 2019, 21, 989-1002.	2.3	15
33	Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castrationâ€resistant prostate cancer cells to enzalutamide. Prostate, 2019, 79, 1347-1359.	1.2	36
34	Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death. PLoS ONE, 2019, 14, e0211090.	1.1	10
35	Abstract 915: Pseudogene-associated recurrent gene fusion in prostate cancer. , 2019, , .		0
36	Genitourinary Pathology Reporting Parameters Most Relevant to the Medical Oncologist. Surgical Pathology Clinics, 2018, 11, 877-891.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Enrichment and mutation detection of circulating tumor cells from blood samples. <i>Oncology Reports</i> , 2018, 39, 2537-2544.	1.2	6
38	Abstract 1803: Dynamic pro-survival signaling mediates resistance to androgen receptor targeted therapy in AR-v7 splice variant expressing prostate cancer models. , 2018, , .		0
39	IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF- $\alpha$ Signaling. <i>Prostate</i> , 2017, 77, 866-877.	1.2	14
40	Immune evaluation study of sipuleucel-T (Sip-T) in African-American and European-American men with castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 206-206.	0.8	1
41	Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 373-380.e2.	0.9	22
42	The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 381-388.	0.9	12
43	Time to castration-resistance and docetaxel outcomes in metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16519-e16519.	0.8	0
44	Abstract 3571: Targeted suppression of inhibitor of apoptosis proteins amplifies apoptosis and improves response to enzalutamide in prostate cancer. , 2016, , .		0
45	Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 166-76.	0.0	6
46	MP87-01 DO PRIMARY HORMONAL THERAPY OUTCOMES PREDICT SUBSEQUENT RESPONSE TO ABIRATERONE OR ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER?. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
47	Use of radium-223 in heavily pretreated metastatic castrate resistant prostate cancer (mCRPC) patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 275-275.	0.8	0
48	Reply to G. Procopio et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3083-3084.	0.8	1
49	Chemotherapeutic inhibitors in the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 11-22.	0.9	4
50	The Judgment of Paris: Treatment Dilemmas in Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 729-734.	0.8	11
51	Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample. <i>PLoS ONE</i> , 2014, 9, e94977.	1.1	6
52	Overcoming docetaxel resistance in prostate cancer: a perspective review. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 329-340.	1.4	114
53	Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM. <i>PLoS ONE</i> , 2012, 7, e33729.	1.1	189
54	Averaged Differential Expression for the Discovery of Biomarkers in the Blood of Patients with Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e34875.	1.1	12

#	ARTICLE	IF	CITATIONS
55	$\beta$ III-tubulin expression as a predictor of docetaxel resistance in metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology, 2012, 30, e15174-e15174.	0.8	0
56	The effects of BR-DIM (BioResponse 3, 3 $\alpha$ -Diindolylmethane) administered pre-prostatectomy on the androgen receptor (AR).. Journal of Clinical Oncology, 2012, 30, 1560-1560.	0.8	0
57	Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. American Journal of Translational Research (discontinued), 2012, 4, 14-23.	0.0	70
58	Angiogenesis inhibitors in the treatment of prostate cancer. Journal of Hematology and Oncology, 2010, 3, 26.	6.9	49
59	Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate, 2010, 70, 1002-1011.	1.2	22
60	Cytoprotective effects of IAPs revealed by a small molecule antagonist. Biochemical Journal, 2009, 417, 765-771.	1.7	42
61	EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor. Breast Cancer Research and Treatment, 2008, 107, 235-242.	1.1	41
62	X-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer model. Cell Death and Differentiation, 2008, 15, 831-840.	5.0	18
63	Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells. Prostate, 2001, 47, 194-204.	1.2	42
64	Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology, 1999, 53, 260-266.	0.5	199
65	Coordinate regulation of Salmonella typhimurium invasion genes by environmental and regulatory factors is mediated by control of hilA expression. Molecular Microbiology, 1996, 22, 703-714.	1.2	444
66	hilA is a novel ompR/toxR family member that activates the expression of Salmonella typhimurium invasion genes. Molecular Microbiology, 1995, 18, 715-727.	1.2	329